Concepedia

Author

Sridevi Rajeeve

Memorial Sloan Kettering Cancer CenterORCID

Also Known As

Kinga Hosszu, S. Rajeeve, Sridevi Rajeeve

128

Publications

296

Citations

10

H-Index

15

Concepts

All Affiliations

Memorial Sloan Kettering Cancer CenterIcahn School of Medicine at Mount SinaiTisch HospitalTisch Cancer InstituteUniversity of California, San Francisco
SR

About

Sridevi Rajeeve is an author at Memorial Sloan Kettering Cancer Center specializing in immunology, hematology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

74

2

Immunology

3

3

74

3

Health Sciences

2

2

61

4

Cellular Therapies

1

1

24

5

Pharmacology

1

1

13

Sridevi Rajeeve

×

11

Publications

199

Citations

10

H-Index

YearCitations

Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma

Tarek H. Mouhieddine, Oliver Van Oekelen, David T. Melnekoff,

Blood Advances

2022

37

Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma

Ross Firestone, Nicholas D. Socci, Tala Shekarkhand,

Blood

2024

35

Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma

Bruno Almeida Costa, Jessica Flynn, Noriko Nishimura,

Blood Cancer Journal

2024

24

T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy

Kai Rejeski, Jaime Sanz, Teng Fei,

Blood

2025

17

Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue

Erel Joffe, Yan Leyfman, Esther Drill,

Blood Advances

2021

16

Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia

Ryan J. Daley, Sridevi Rajeeve, Charlene Kabel,

Leukemia & lymphoma/Leukemia and lymphoma

2020

13

Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Anupama Kumar, Suheil Albert Atallah‐Yunes, Sridevi Rajeeve,

Blood

2024

13

Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes

Charlotte B Wagner, Kenneth M. Boucher, Adrienne Nedved,

Haematologica

2023

12

Real-world schedule de-escalation of teclistamab in patients with relapsed/refractory multiple myeloma.

Carlyn Tan, Andriy Derkach, Kylee Maclachlan,

Journal of Clinical Oncology

2024

12

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia

Zachary D. Epstein‐Peterson, Andriy Derkach, Susan M. Geyer,

Blood Advances

2022

10

Page 1